Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States

被引：0
|
作者：
Farber, Harrison W. [1 ]
Germack, Hayley D. [2 ]
Croteau, Nicole S. [3 ]
Simeone, Jason C. [3 ]
Tang, Fei [3 ]
Paoli, Carly J. [2 ]
Doad, Gurinderpal [4 ]
Panjabi, Sumeet [2 ]
De Marco, Teresa [5 ]
机构：
[1] Tufts Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02111 USA
[2] Janssen Sci Affairs LLC, Titusville, NJ USA
[3] Cytel, Real World Evidence, Waltham, MA USA
[4] Actelion Pharmaceut, Titusville, NJ USA
[5] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA
来源：
PULMONARY CIRCULATION | 2024年 / 14卷 / 02期
关键词：
pulmonary arterial hypertension; risk factors; treatment;
D O I：
10.1002/pul2.12326
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Information on factors leading to pulmonary arterial hypertension (PAH) treatment discontinuation is limited. This study analyzed 12,902 new PAH medication users to identify predictors of treatment discontinuation. Treatment by accredited pulmonary hypertension centers and combination therapy with PAH agents from different classes were less likely to result in discontinuation.
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Selexipag for the treatment of pulmonary arterial hypertension
    Noel, Zachary R.
    Kido, Kazuhiko
    Macaulay, Tracy E.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (15) : 1135 - 1141
  • [32] Macitentan for the treatment of pulmonary arterial hypertension
    DuBrock, Hilary M.
    Channick, Richard N.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2014, 8 (04) : 393 - 399
  • [33] Treprostinil in the treatment of pulmonary arterial hypertension
    Feldman, Jeremy
    Habib, Naomi
    Fann, Jade
    Radosevich, John J.
    FUTURE CARDIOLOGY, 2020, 16 (06) : 547 - 558
  • [34] Selexipag for the treatment of pulmonary arterial hypertension
    Sharma, Kamal
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (01) : 1 - 3
  • [35] Guidelines for the Treatment of Pulmonary Arterial Hypertension
    Vazquez, Zoe G. S.
    Klinger, James R.
    LUNG, 2020, 198 (04) : 581 - 596
  • [36] Medical Treatment of Pulmonary Arterial Hypertension
    Adamali, Huzaifa
    Gaine, Sean P.
    Rubin, Lewis J.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 30 (04) : 484 - 492
  • [37] Riociguat in the Treatment of Pulmonary Arterial Hypertension
    Jerjes-Sanchez, Carlos
    Glenn-Valdez, Hector
    Zayas, Nayeli
    Cueto-Robledo, Guillermo
    Bonola, Liliana
    Pech-Alonso, Baltazar
    Ramirez, Alicia
    Flores-Puente, Fernando
    Garcia-Aguilar, Humberto
    Espitia-Hernandez, Guadalupe
    Prisciliano Montes, Guillermo
    Pulido, Tomas
    ARCHIVES OF MEDICAL RESEARCH, 2022, 53 (04) : 352 - 358
  • [38] Pharmacologic Treatment of Pulmonary Arterial Hypertension
    Ramani, Gautam V.
    Gill, Sartraj
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (22) : 3963 - 3973
  • [39] Surgical Treatment of Pulmonary Arterial Hypertension
    Dartevelle, Philippe G.
    PULMONARY ARTERIAL HYPERTENSION: FOCUSING ON A FUTURE: ENHANCING AND EXTENDING LIFE, 2010, 10 : 5 - 11
  • [40] Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension
    Segura-Ibarra, Victor
    Wu, Suhong
    Hassan, Nida
    Moran-Guerrero, Jose A.
    Ferrari, Mauro
    Guha, Ashrith
    Karmouty-Quintana, Harry
    Blanco, Elvin
    FRONTIERS IN PHYSIOLOGY, 2018, 9
12345